Genmab — November 2018
-
Vi har arbejdet sammen før. Nu fik vi muligheden igen.
-
God morgen.

-
NEJM : Daratumumab for Delayed Red-Cell Engraftment after Allogeneic Transplantation https://www.nejm.org/doi/full/10.1056/NEJMoa1807438
-
New trial: Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction (IDA53) https://clinicaltrials.gov/ct2/show/NCT03734198
-
God morgen

-
-
The SC combo trial adds an extra arm, (D-Kd)
https://clinicaltrials.gov/ct2/history/NCT03412565?A=12&B=13&C=merged -
Thanks El. Og lidt apropos: WM cell lines treated with the ibrutinib + Dara combination, showed significantly more cell death through ADCC, CDC, ADCP and apoptosis relative to single‐agent Dara or ibrutinib. In summary, we are the first to report the in vitro and in vivo anti‐WM activity of Dara. Furthermore, we show a close connection between BCR and CD38 signalling, which can be co‐targeted with ibrutinib + Dara to induce marked WM cell death.(British Journal of Haematology 183(2) · August18
-
Det passer vel også meget godt - var det ikke ca. 1 nov. at AB begyndte at ligge som største nettokøber mange af dagene?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind